Boehringer Ingelheim Hepatitis C Drugs Cured 82% in Trial

StephenW

                Boehringer Ingelheim Hepatitis C Drugs Cured 82% in Trial
                                                                                          By                    Makiko Kitamura                 -                                Apr 19, 2012 7:00 PM ET                          
                              
                     

•               
  
  

        
                                                 April 19 (Bloomberg) --Boehringer Ingelheim GmbH said itsexperimental hepatitis C oral treatment cleared the virus in asmany as 82 percent of patients in a study.
The mid-stage Sound-C2 trial followed 362 patients whohadn’t received other treatments before taking the Ingelheim,Germany-based drugmaker’s BI 201335 protease inhibitor and BI207127 polymerase inhibitor combined with ribavirin.
Researchers reported an 82 percent cure rate among patientswith the most common type of hepatitis C after 28 weeks oftreatment, Boehringer said today at the European Association forthe Study of the Liver annual meeting in Barcelona. Among allpatients studied, 68 percent were cured.
The trial didn’t include interferon, an injected drug whichis combined with ribavirin and a protease inhibitor as thecurrent standard of care. Protease inhibitors block the actionof the protease enzyme that the hepatitis virus needs toreplicate, stopping it from spreading. Drugmakers includingGilead Sciences Inc. (GILD) and Bristol-Myers Squibb Co. (BMY) are alsoseeking to remove interferon from the treatment regimen becauseof flu-like side effects.
“Eliminating interferon from HCV treatment is an urgentneed,” Stefan Zeuzem, chief of the department of medicine atJohann Wolfgang Goethe University Hospital in Frankfurt and leadinvestigator of the study, said in a statement. “Releasingpatients from the side effects and the lengthy treatmentcommitment seen with interferon would be a huge advance.”
Abbott’s Test Results Earlier this month, Abbott Laboratories (ABT) said itsexperimental hepatitis C treatment, combining the ABT-450protease inhibitor, ABT-333 NS5B polymerase inhibitor, ritonavirand ribavirin, cured 47 percent of patients who couldn’teliminate the virus with prior therapies. Those who had neverbeen treated had a cure rate of 93 percent to 95 percent, theU.S. company said.
Hepatitis C affects as many as 170 million people globally,putting them at risk of developing liver cancer, according tothe World Health Organization. The growing population ofpatients infected with the virus spurred Gilead’s decision inNovember to buy experimental hepatitis C-treatment makerPharmasset Inc. for $10.8 billion and Bristol-Myers’sacquisition in February of Inhibitex Inc. for $2.5 billion.
The disease is most commonly transmitted throughcontaminated blood transfusions, organ transplants, contaminatedsyringes and needle-injected drug use, according to the WHO.
To contact the reporter on this story:Makiko Kitamura in Barcelona via [email protected]

StephenW

勃林格殷格翰丙型肝炎药物治愈82％，在审判
田中真纪子北村 -  2012年04月19日下午7:00 ET

4月19日（彭博） - 勃林格殷格翰公司表示，其实验丙型肝炎的口服治疗，清除病毒，多达82％的患者在研究中。

中期阶段的声音-C2的试用之后362谁没有收到其他前殷格翰，德国的制药公司的BI 201335蛋白酶抑制剂的BI 207127聚合酶抑制剂联合利巴韦林治疗的患者。

研究人员报告与C型肝炎最常见的类型，治疗28周后，患者治愈率达82％之间，勃林格今天说，在肝研究年度会议在巴塞罗那的欧洲协会。在所有研究的患者中，68％被治愈。

该试验不包括干扰素联合利巴韦林和蛋白酶抑制剂作为现行标准的护理，注射毒品。蛋白酶抑制剂阻断蛋白酶肝炎病毒复制，阻止火势蔓延的行动。包括Gilead Sciences公司（GILD）和施贵宝公司（BMY牛）的制药公司也在寻求从干扰素治疗方案，因为类似感冒的副作用。

“消除从HCV治疗的干扰素是一个迫切的需要”，在法兰克福约翰·沃尔夫冈·歌德大学医院的内科主任和研究的首席研究员，斯特凡Zeuzem在一份声明中说。 “病人的副作用和干扰素看到漫长的治疗承诺释放将是一个巨大的进步。”
雅培的​​测试结果

本月早些时候，雅培（ABT生根粉）说，实验的丙型肝炎治疗相结合的ABT  -  450蛋白酶抑制剂ABT-333 NS5B聚合酶抑制剂，利托那韦和利巴韦林，治愈47％的病人事先疗法不能消除病毒。那些从未治疗过的93％，治愈率达95％，这家美国公司说。

C型肝炎在全球的影响多达170万人，他们把发展肝癌的风险，根据世界卫生组织。与病毒感染的患者不断增长的人口，带动11月Gilead公司的实验性肝炎治疗的C制造商Pharmasset公司决定在2月Inhibitex公司购买25亿美元为10.8亿元和百时美施贵宝公司收购。

本病是最常见的传播通过受污染的输血，器官移植，受污染的注射器和针头注射毒品使用，根据世界卫生组织。

要联系本故事记者：田中真纪子在巴塞罗那北村通过[email protected]